Catalysts await as we climb towards $100 pps - technically, this stock is bulletproof. Earnings are estimated first week of August, prepare for a revenue and earnings beat and upgraded forecast. Stay long my friends...
Sentiment: Strong Buy
I am speculating but I would bet the recent run has to do with the numbers for next quarter.
As results come in they could be blowing projections out of the water.
My opinion DXCM easily breaks $80 after August earnings call.
Question will DXCM break $100 before the end of the year.
Remember they were priced at $33.00 on 6/13/14 about 1 year ago.
I own this stock and have made money on it. I notice that this message board is not very active but I'm wondering if anyone on it has a real knowledge of this company and it's future. Who are it's major competitors and whether it's really the time to get out. Let's discuss it professionally if you know anything.
I am long and enjoying the ride. I have NO idea how high it will go or when. Assuming the tape stays (at least) benign, there seem to be lots of large buyers pushing the stock higher. No indication to believe the trend will change yet. Stock is very expensive but they have terrific technology. If you're worried, set a stop. Otherwise, relax and enjoy the run.
Dexcom's revenue growth has been a steady 60% for the last six quarters.
They have the only CGM device with FDA approval.
Their sensor gross margins are at 70%.
CGM eliminates conventional meters, strips, lancing devices.
Also eliminating the need for a patient draw blood, while giving true glucose levels not attainable with current strips and meters..
Bottom line Dexcom in the near future will dominate and own the 30 billion glucose monitoring industry.
The business of glucose monitoring is growing at a fast rate of 25% annually, and experts estimate that by 2017, the market will exceed $30 billion worldwide.
Dexcom's revenues have grown north of 60% annually for the last six quarters and their cash based income has increased threefold over the same quarter last year. Gross margins on their G4 Platinum sensor is between 70% and 75% and the gross margins for the hardware is 50% or better. Given that the data on the increasing level of new patients, their current retention rate and replacement hardware all looks positive, we continue to like how the company is positioned for growth. With two of the next generation sensors in development (the G5 and G6) we continue to believe DexCom will remain
I must agree. The stock is incredibly strong. Any modest pullback is immediately bought. The chart is as good as it can get. $100 seems possible.
Kicking myself for selling when I did even though I made a ton but the sky's the limit for DXCM
who understands that a good company may not be a good investment (Investing 101). When the P/sales on this stock goes back to 10 (or lower) the price will be cut in half. And there is more......but the lemmings on this board are 100% against hearing anything that will burst the dream world they live in.....so I will let them learn the other things on their own (and the hard way).
"The G5 announcement has a great chance of helping the company accelerate its already torrid growth rate, which could allow the stock to continue its market-beating ways from today's nosebleed valuation. However, as bullish as I am on the company's competitive position in the market and its huge opportunity ahead, its stock is simply far too richly valued for my taste. Until the company trades at a more reasonable valuation, I'm content to keep my distance from the stock and will continue to root from the sidelines for this diabetes winner to keep on advancing."
All of you who have been with this stock for the last 2 years and made good money should now be thinking that this company has run it's race and is stagnating, it has gone as far as it can and made you good returns.
Now's it's time to move on to the next one and invest in $ECTE get in now while it's still under $2 you know it makes sense
Just about two weeks ago, Kevin Sayer spoke at the William Blair Conference on 6/9 - any investor or future investor in Dexcom should listen to the webcast; it is only 55 minutes long. This company is on solid footing and has enormous potential - just listen and decide for yourself. The presentation is under "Investor Relations" -- "Events and Presentations".
Doc, i don't know your background, but as a dexcom user (I have no stake in the company) I believe you're mistaken. first they actually have a brilliant business model the Animas pump from J&J is integrated with the Dexcom, the Omni Pod is working on it, where both the dexcom and pods will be controlled by smart phone. T:Slim by Tandem is awaiting FDA Clearance on their integrated G4 puump. accuracy of the g4 surpasses the medtronics cgm. many times I check the dexcom then take a blood test and the numbers are the same! They set themselves up that any pump company can develop an integrated pump as long as they conform to the dexcom standard, which means they will set the standard since they are not competing with the pump manufacturers.
you are in the state of euphoria. You forgot about minimed by mdt. minimed artificial pancreas sells way more than dxcm for years.
no. medtronics has the same CGM systems used in combination with the minimed pump. medtronics CGM system is there, but hasn't marketed it hard. There are lots of insurance coverage issues too. DXCM is a solid company. However, it is a one trick pony. MDT or others can really cause problems down the line. They have money to run trials. Besides, getting continuous monitoring is nice, but it is not a must. The market is a niche and small market where DXCM is in. It is nice to know your sugars throughout the day. However, What you do with the CGM data is the key point. That is why it is combined with an insulin pump. Old diabetics are not going to want to know it. It will be too scary or complicated for most old diabetics. Young diabetics are mostly insulin dependent and they want insulin pumps with CGM. I worry about this before I invest in DXCM. The analysts are pumping for their private clients. I have no positions at this time and DXCM is running up too much this year.
BlackRock, Inc. just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13G. In the filing, it appears as though BlackRock, Inc. claims to own 3639404 shares. This represents 4.6% of DexCom.
Sentiment: Strong Buy
2014 revenues for the Glucose monitoring industry as a whole were 10 Billion dollars and Dexcom recorded just 257 Million for the same period, It is easy to see why Dexcom's potential for revenue growth is off the charts.
Dexcom had .only 0.0257 percent of a 10 Billon Dollar market last year.
There is no reason that I see to prevent Dexcom from capturing 10% percent of the market by 2016 bringing revenues up from the current $257 Million to $1 Billion.
A $100 DXCM stock price if there are no hiccups seems to be a forgone conclusion.
From Forbes 2014-2019 Global Glucose Market
Press Release | Thu Apr 24, 2014 4:35am EDT:
The global glucose monitoring devices market value will experience a moderate increase from $9.9 billion in 2012 to $13.7 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%Glucose Monitoring Device Market 2014-2019 looks at the market, competitive landscape, and trends for the three glucose monitoring devices market segments: blood glucose meters, blood glucose testing strips, and lancets.
After hours trading point to $100 a share price tomorrow.
I thought DXCM would break the $100 barrier but expected it to be after they reported 3rd quarter results.
By partnering with Google and being featured on Cramer's Mad Money it happens Friday.
Next stop $200.00